Logo
x

Search

Subscribe Now

arcutis

PharmaShots Weekly Snapshots (February 26 – March 01, 2024)

PharmaShots Weekly Snapshots (February 26 – March 01, 2024)

  • March 1, 2024
Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Arcutis Receives the US FDA Approval for Zoryve (roflumilast) to Treat Seborrheic Dermatitis in Individuals Aged 9 Years and Older

  • December 18, 2023
Arcutis Reports Interim Results from the P-III (INTEGUMENT-OLE) Trial of Roflumilast for Mild to Moderate Atopic Dermatitis

Arcutis Reports Interim Results from the P-III (INTEGUMENT-OLE) Trial of Roflumilast for Mild to Moderate Atopic Dermatitis

  • September 9, 2023
Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia

Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia

  • August 11, 2023
Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years

Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years

  • April 19, 2023
Arcutis Reports the NDA Submission of Roflumilast to the US FDA for the Treatment of Seborrheic Dermatitis

Arcutis Reports the NDA Submission of Roflumilast to the US FDA for the Treatment of Seborrheic Dermatitis

  • February 22, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.